PMID- 23074549
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121018
LR  - 20211021
IS  - 2070-5204 (Electronic)
IS  - 1999-768X (Print)
IS  - 1999-768X (Linking)
VI  - 27
IP  - 5
DP  - 2012 Sep
TI  - Synthesis and Anti-hyperlipidemic Activity of 3H-benzo [4, 5] thieno [2, 3-d] [1, 
      2, 3] triazin-4-ones: Possible Mechanism of Altered Lipid Metabolism.
PG  - 388-95
LID - 10.5001/omj.2012.96 [doi]
AB  - OBJECTIVES: The present study was aimed to evaluate the anti-hyperlipidemic 
      activity of newly synthesized tricyclic benzothieno 1, 2, 3-triazine derivatives 
      namely CP-1 (3-(methyl)- 5,6,7,8-tetrahydro,3H-benzo[4,5] thieno [2,3-d][1,2,3] 
      triazin-4-one), CP-2 (3-(ethyl)- 5,6,7,8-tetrahydro,3H-benzo[4,5] thieno 
      [2,3-d][1,2,3] triazin-4-one) and CP-6 (3-(2-chloro 
      phenyl)-5,6,7,8-tetrahydro,3H-benzo[4,5] thieno [2,3-d][1,2,3] triazin-4-one) 
      against dexamethasone and Triton WR-1339-induced hyper-lipidemia in rats. 
      METHODS: Anti-hyperlipidemic activity of the test compounds were evaluated 
      against dexamethasone (10 mg/kg, subcutaneous [s.c.]) and Triton WR-1339 (200 
      mg/kg, intraperitoneal [i.p]) induced hyperlipidemia in rats. RESULTS: 
      Administration of single dose of Triton WR-1339 (200 mg/kg i.p) and dexamethasone 
      (10 mg/kg s.c.) for 8 consecutive days to adult wistar rats caused severe 
      hyperlipidemia characterized by marked increase in serum cholesterol, LDL-C, 
      VLDL-C and triglyceride levels along with an increase in atherogenic index. Serum 
      HDL-C levels were decreased significantly compared to normal control. 
      Pretreatment with Atorvastatin (10 mg/kg, p.o.), CP-1 (25 and 50 mg/kg), CP-2 (25 
      and 50 mg/kg) and CP-6 (25 and 50 mg/kg) showed significant and dose-dependent 
      protection against dexamethasone and Triton WR-1339-induced hyperlipidemia in 
      rats by maintaining serum total cholesterol, LDL-C, VLDL-C and HDL-C levels 
      within the normal range. Also, a significant decrease in atherogenic index was 
      observed. The anti-hyperlipidemic effect of CP-6 was comparable with reference 
      standard Atorvastatin. Furthermore, CP-6 was found to be more potent than CP-1 
      and CP-2. CONCLUSION: These findings suggest that CP-1, CP-2 and CP-6 possess 
      significant anti-hyperlipidemic activity against experimental animal models of 
      hyperlipidemia.
FAU - Viswanatha, Gollapalle L
AU  - Viswanatha GL
AD  - Department of Pharmacology, PES College of Pharmacy, Bangalore-560050.
CN  - Janaki Priyadarshini B
FAU - Hanumanthappa, Shylaja
AU  - Hanumanthappa S
FAU - Rangappa, Srinath
AU  - Rangappa S
FAU - Janardhanan, Saravanan
AU  - Janardhanan S
LA  - eng
PT  - Journal Article
PL  - Oman
TA  - Oman Med J
JT  - Oman medical journal
JID - 101526350
PMC - PMC3472570
OTO - NOTNLM
OT  - 1, 2, 3-Triazine-4-ones
OT  - Dexamethasone
OT  - Diazotization
OT  - Gewald reaction
OT  - Hyperlipidemia
OT  - Thiophenes
OT  - Triton WR-1339
EDAT- 2012/10/18 06:00
MHDA- 2012/10/18 06:01
PMCR- 2012/09/01
CRDT- 2012/10/18 06:00
PHST- 2012/04/02 00:00 [received]
PHST- 2012/06/25 00:00 [accepted]
PHST- 2012/10/18 06:00 [entrez]
PHST- 2012/10/18 06:00 [pubmed]
PHST- 2012/10/18 06:01 [medline]
PHST- 2012/09/01 00:00 [pmc-release]
AID - OMJ-D-12-00025 [pii]
AID - 10.5001/omj.2012.96 [doi]
PST - ppublish
SO  - Oman Med J. 2012 Sep;27(5):388-95. doi: 10.5001/omj.2012.96.